Drug Profile
NXN 462
Alternative Names: NXN-462Latest Information Update: 08 Sep 2021
Price :
$50
*
At a glance
- Originator NeurAxon
- Class Non-opioid analgesics; Small molecules
- Mechanism of Action Nitric oxide synthase type I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Migraine; Parkinsonian disorders; Postherpetic neuralgia
Most Recent Events
- 08 Sep 2021 Discontinued - Phase-I for Migraine in Canada (PO) (Knight Therapeutics pipeline, September 2021)
- 08 Sep 2021 Discontinued - Phase-II for Parkinsonian disorders in Canada (PO) (Knight Therapeutics pipeline, September 2021)
- 08 Sep 2021 Discontinued - Phase-II for Postherpetic neuralgia in Canada (PO) (Knight Therapeutics pipeline, September 2021)